MX9706140A - Composiciones de aminoacidos y el uso de las mismas en nutricion clinica. - Google Patents

Composiciones de aminoacidos y el uso de las mismas en nutricion clinica.

Info

Publication number
MX9706140A
MX9706140A MX9706140A MX9706140A MX9706140A MX 9706140 A MX9706140 A MX 9706140A MX 9706140 A MX9706140 A MX 9706140A MX 9706140 A MX9706140 A MX 9706140A MX 9706140 A MX9706140 A MX 9706140A
Authority
MX
Mexico
Prior art keywords
tnf
amino acid
diminution
levels
acid compositions
Prior art date
Application number
MX9706140A
Other languages
English (en)
Other versions
MXPA97006140A (es
Inventor
Heinz Schneider
Ronald G Thurman
Original Assignee
Novartis Nutrition Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08392694 external-priority patent/US5656608B1/en
Priority claimed from GBGB9512100.0A external-priority patent/GB9512100D0/en
Application filed by Novartis Nutrition Ag filed Critical Novartis Nutrition Ag
Publication of MX9706140A publication Critical patent/MX9706140A/es
Publication of MXPA97006140A publication Critical patent/MXPA97006140A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12Fatty acids or derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13Nucleic acids or derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/175Amino acids
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pediatric Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)

Abstract

La presente invencion proporciona el uso de al menos un aminoácido seleccionado del grupo que consiste de la glicina, alanina y serina, o las sales fisiologicamente aceptables de los mismos, en la preparacion de un medicamente o formulacion nutricional, para la disminucion de los niveles del factor de la necrosis en tumores (TNF) en pacientes en quienes esos niveles están elevados más allá de aquéllos que median la homeostasis fisiologica y la inflamacion local. Esa disminucion de los niveles del TNF se pueden lograr, inter alia, mediante la inhibicion o disminucion de: (i) la produccion del factor de la necrosis de tumores (TNF) por células del tipo macrofagos; (ii) la liberacion del TNF por células del tipo macrofagos; y/o (iii) el enlazamiento del TNF por receptores del TNF.
MXPA/A/1997/006140A 1995-02-23 1997-08-12 Composiciones de aminoacidos y el uso de las mismas en nutricion clinica MXPA97006140A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08392694 1995-02-23
US08392694 US5656608B1 (en) 1995-02-23 1995-02-23 Amino acid compositions and methods of treatment using same
GB9512100.0 1995-06-14
GBGB9512100.0A GB9512100D0 (en) 1995-06-14 1995-06-14 Improvements in or relating to organic compounds
PCT/EP1996/000739 WO1996025861A1 (en) 1995-02-23 1996-02-22 Amino acid compositions and use thereof in clinical nutrition

Publications (2)

Publication Number Publication Date
MX9706140A true MX9706140A (es) 1997-11-29
MXPA97006140A MXPA97006140A (es) 1998-07-03

Family

ID=

Also Published As

Publication number Publication date
EP0810829B1 (en) 2000-04-12
CA2210499A1 (en) 1996-08-29
CZ266797A3 (cs) 1998-03-18
ES2145997T3 (es) 2000-07-16
PL182205B1 (pl) 2001-11-30
NO973884D0 (no) 1997-08-22
NO973884L (no) 1997-10-17
PT810829E (pt) 2000-08-31
PL321238A1 (en) 1997-11-24
DE69607750D1 (de) 2000-05-18
HUP9800049A2 (hu) 1998-05-28
ATE191615T1 (de) 2000-04-15
WO1996025861A1 (en) 1996-08-29
BR9607336A (pt) 1997-11-25
HUP9800049A3 (en) 1999-01-28
EP0810829A1 (en) 1997-12-10
JPH11501301A (ja) 1999-02-02
DE69607750T2 (de) 2000-08-31
DK0810829T3 (da) 2000-08-28
AU4879596A (en) 1996-09-11
KR19980702436A (ko) 1998-07-15
CN1175887A (zh) 1998-03-11
FI972744A0 (fi) 1997-06-25
AU710527B2 (en) 1999-09-23
FI972744A (fi) 1997-08-22

Similar Documents

Publication Publication Date Title
AU4879596A (en) Amino acid compositions and use thereof in clinical nutrition
CA2229279A1 (en) Nutritional and/or dietary composition and method of using the same
MX9504034A (es) Formas de administracion medicamentosas que contienen acido tioctico, o sales solidas del acido tioctico de liberacion y biodisponibilidad mejoradas.
CA2371696A1 (en) Composition for an infant formula having a low threonine content
IL141021A (en) Use of copolymer-like polypeptide-1 to prepare a drug to treat autoimmune diseases
BG103335A (en) Application of fumaric acid derivatives
CA2329005A1 (en) Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
IL112111A0 (en) Peptide derivatives and pharmaceutical compositions containing them
EP0797999A3 (en) Formulations of obesity protein
MXPA02012064A (es) Complejos de farmaco macromoleculares y composiciones que los contienen.
HK1030160A1 (en) Methods of enhancing functioning of the upper gastrointestinal tract
HK1085927A1 (en) The use of lupin conglutin for the preparation of a medicament, food supplements or foods for the treatment of type ii diabetes
EP0825197A3 (en) New 6-hydroxy and 6-oxo-anstro-stane derivatives active on the cardiovascular system and pharmaceutical compositions containing same
MY124560A (en) Amino acid compositions and use thereof in immunosuppression
WO2002058589A3 (en) Agents and methods for promoting bone growth
IL161670A0 (en) Thymosin alpha 1 peptide/polymer conjugates
Wildburger et al. Comparison of the values of basic fibroblast growth factor determined by an immunoassay in the sera of patients with traumatic brain injury and enhanced osteogenesis and the effects of the same sera on the fibroblast growth in vitro
WO2003049687A3 (en) Medicinal compositions & therapeutic methods
EP0855181A3 (en) Medicament or nutritional formulation for immune-modulation with amino acids
NZ336043A (en) Use of COMT inhibitors for preventing diabetic vascular dysfunctions or neuropathy
HUP0302294A2 (hu) L-karnitin és alkanoil-L-karnitin taurin-kloriddal és glicin-kloriddal alkotott nem higroszkópos sói és ezeket tartalmazó, orális beadásra alkalmas szilárd készítmények
GB8804188D0 (en) Pharmaceutical compositions
IL131956A0 (en) Solid compositions suitable for oral administration comprising non hygroscopic salts of l-carnitine and alkanoyl-l-carnitine with 2-aminoethanesulfonic acid
Wang et al. Effects of arginine-devoid diets in chronically uremic rats